Indivior Pharmaceuticals, Inc. will eliminate the Chief Scientific Officer position effective June 1, 2026, and Dr. Christian Heidbreder's employment will end on December 31, 2026, treated as termination without cause. Additionally, a virtual annual meeting held on May 13, 2026, saw 100,407,725 shares voted, electing directors and approving executive compensation with majority support.